Adherence to human lung microvascular endothelial cells (HMVEC-L) of *Plasmodium vivax* isolates from Colombia

Briegel De las salas1, Cesar Segura1, Adriana Pabón1,2, Stefanie CP Lopes3, Fabio TM Costa3 and Silvia Blair1*

**Abstract**

**Background:** For years *Plasmodium vivax* has been considered the cause of benign malaria. Nevertheless, it has been observed that this parasite can produce a severe disease comparable to *Plasmodium falciparum*. It has been suggested that some physiopathogenic processes might be shared by these two species, such as cytoadherence. Recently, it has been demonstrated that *P. vivax*-infected erythrocytes (*Pv-iEs*) have the capacity to adhere to endothelial cells, in which intercellular adhesion molecule-1 (ICAM-1) seems to be involved in this process.

**Methods:** Adherence capacity of 21 Colombian isolates, from patients with *P. vivax* mono-infection to a microvascular line of human lung endothelium (HMVEC-L) was assessed in static conditions and binding was evaluated at basal levels or in tumor necrosis factor (TNF) stimulated cells. The adherence specificity for the ICAM-1 receptor was determined through inhibition with an anti-CD54 monoclonal antibody.

**Results:** The majority of *P. vivax* isolates, 13 out of 21 (61.9%), adhered to the HMVEC-L cells, but *P. vivax* adherence was at least seven times lower when compared to the four *P. falciparum* isolates. Moreover, HMVEC-L stimulation with TNF led to an increase of 1.6-fold in *P. vivax* cytoadhesion, similar to *P. falciparum* isolates (1.8-fold) at comparable conditions. Also, blockage of ICAM-1 receptor with specific antibodies showed a significant 50% adherence reduction.

**Conclusions:** *Plasmodium vivax* isolates found in Colombia are also capable of adhering specifically *in vitro* to lung endothelial cells, via ICAM-1 cell receptor, both at basal state and after cell stimulation with TNF. Collectively, these findings reinforce the concept of cytoadherence for *P. vivax*, but here, to a different endothelial cell line and using geographical distinct isolates, thus contributing to understanding *P. vivax* biology.

**Keywords:** Cytoadherence, *Plasmodium vivax*, Malaria, ICAM-1, Microvascular line of human lung endothelium, Colombia

**Background**

It has been estimated that *Plasmodium vivax* causes around 80–300 million cases per year, mainly in the Asian and Latin American regions [1]. For a long time *P. vivax* was considered the cause of benign malaria [1]. Nevertheless, it has been observed that this species can cause severe disease similar to *Plasmodium falciparum* and complications caused by *P. vivax* mono-infection have been described, such as cerebral malaria with generalized seizures and epileptic status, severe anaemia, hepatic dysfunction and jaundice, acute lung lesion, acute respiratory distress syndrome (ARDS) and pulmonary oedema, shock, splenic rupture, acute renal failure and acute thrombocytopenia with or without bleeding on different body sites [2-9]. Most recently, goes back to 2008 with the acquisition of *P. vivax* genomic sequence, it was found that around 80% of the genes are orthologous and mostly syntenic between the *P. vivax* and *P. falciparum* genomes [10-12]. Taken together this suggests that *P. falciparum* malaria pathogenic processes related to cytoadhesion may occur in *P. vivax* [13]. Furthermore, studies performed by Anstey
et al. suggested that pulmonary lesions found in *P. vivax* malaria could be caused by sequestration of parasitic forms within this organ [14]. In this sense, Carvalho *et al.* reported that *P. vivax* has the ability to cytoadhere *ex vivo* to human lung endothelial cells (HLEC) and, to a lesser extent, to placenta cryosections [13]. Accordingly, Chotivanich *et al.* demonstrated that *P. vivax* isolates from Thailand have the ability to adhere to chondroitin sulphate A (CSA) and to hyaluronic acid (HA) in placental sections [15-18]. Moreover, in 2012, Bernabeu *et al.* reported the participation of vir 14 protein in the adherence to ICAM-1 receptor on the Chinese hamster ovary (CHO) cells transfected with human ICAM-1 (CHO-ICAM-1) cell line [18].

In Colombia, *P. vivax* continues to cause high impact on public health, with 83,255 (70.7%) cases in 2010, from a total of 117,650 reported malaria cases. Severe *P. vivax* malaria cases have been described primarily in newborn, children and pregnant women [9,19,20]. Due to the emergence of complications caused by *P. vivax* infection and its cytoadherence capacity, the purpose of this study was to determine the adherence capacity of *Pv*-iEs from Colombian patients, to human lung endothelial cells (HMVEC-L) mediated by ICAM-1 receptor in static conditions.

**Methods**

**Ethical considerations**

This study was approved by the Faculty of Medicine of the University of Antioquia’s ethics committee records 012 – 18 June, 2009. All participants agreed to voluntarily donate their blood samples after signing an informed consent.

**Study area and subjects**

Up to 8.5 ml of peripheral blood was collected from 21 *P. vivax* non-complicated malaria patients, diagnosed by the thick-smear method and confirmed by rapid diagnostic test (Bioline SD05FK80) and polymerase chain reaction (PCR) (to dismiss mixed infections at low levels). Seven patients, all different from different places of the Department of Antioquia, were recruited at the University of Antioquia Malaria Group office in Medellin, and the remaining 14, at the Nuestra Señora del Carmen Hospital in El Bagre – Bajo Cauca- Department of Antioquia (7° 35’ 0” N, 74° 48’ 0” W). To compare the *P. vivax* isolates adhesion, four *P. falciparum* isolates were adapted to *in vitro* culture [21].

**Isolation and concentration of Plasmodium vivax mature forms**

The methodology described by Carvalho *et al.* [13] was followed with few modifications. The initial patient parasitaemia was determined by counting the different parasitic forms in 200 leucocytes with an 8,000 leucocytes standard in order to obtain the amount of parasites per μL. Samples were processed immediately after blood collection [22]. Plasma was removed by centrifugation at 2,500 rpm; for removal of WBC, blood was filtered with a Whatman CF11 cellulose column, the resultant pellet was washed three times with RPMI 1640 (Sigma) pH 7.2 medium, and resuspended to a 10% haematocrit. Later, the *Pv*-iEs with mature forms (trophozoites, schizonts and gametocytes) were concentrated and separated from the young stages (rings) and non-infected erythrocytes. For this purpose, 5 mL of the 10% erythrocytes suspension were overlaid on 5 mL of 45% Percoll solution (Sigma P1644) and then the mixture was centrifuged at 2,500 rpm for 20 min at 4°C. The interphase containing mature forms was washed three times with RPMI-1640 pH 7.2. Mature stages were observed by thin smears (Figure 1). The estimated percentage of mature forms and the number of *Pv*-iEs per ml was obtained using the Neubauer chamber count (0.0025 sq mm).

---

**Figure 1** Percoll concentration, before and after enrichment 45% Percoll gradient concentration of the mature stages of *P. vivax*. 1% Giemsa stain of trophozoites, schizonts and gametocytes. 100x objective.
Cultivation of *Plasmodium falciparum* blood forms

*Plasmodium falciparum* FCR3/Gambia strain (donated by National Institutes of Health- NIH, Laboratory of Malaria and Vector Research) were cultured following Trager and Jensen’s method [21]. Mature stages concentration was carried out using 60% Percoll [23].

Isolation and concentration of *Plasmodium falciparum* mature forms harvested from infected patients

The four field *P. falciparum* isolates were adapted to an *in vitro* culture and were maintained as described for FCR3 strain. The mature concentration stages were obtained with 1% Gelatin flotation (Sigma G2625) [24]. The percentage of mature forms, and the number of *P. falciparum*-infected erythrocytes by ml were estimated using the Neubauer chamber count, as previously described [25].

Human lung endothelial cells (HMVEC-L) culture

The HMVEC-L was maintained following the distributor's protocol (Lonzar CC-2527), in endothelial basal medium -2 (EBM-2) (CC-3156) supplemented with endothelial growth medium (EGM-2) MV BulletKit from Lonza-Clonetics (CC-3202) at 37°C and 5% CO₂, endothelial growth medium (EGM-2) MV BulletKit 5×10⁴ Percoll-enriched parasites per well were incubated seeded in Lab-Tek II chambers (Brand-Products), and conditions

Statistical analysis

The statistical significance of the performed comparisons was determined using the Mann–Whitney *U* test. Calculations were performed using the IBM-SPSS Statistics 21 program, and the charts with the Prism Software (6.01 version; GraphPad Software). Differences were considered significant when a *p* < 0.05.

Results

A total of 21 *P. vivax* isolates confirmed through PCR were included. Average parasitaemia was 7,604.7 ± 6,963 parasites/μL. These isolates came from different regions of Antioquia, mainly from Bajo-Cauca, and presented >60% mature asexual stages predominance. The average age of the 21 patients was 28.4 ± 14.1 years and 15 (71.4%) of them were males. The average parasitaemia of the adherent isolates was 9,461.5 ± 4,280.6 parasites/μL (Table 1). Thirteen *P. vivax* isolates (61.9%) presented adherence to HMVEC-L both at basal state and when cells were stimulated with TNF. The average basal state of *Pv*-iEIs per 200 HMVEC-L was 32.5 ± 19.1; and after TNF stimulation a 1.6-fold increasing (52.1 ± 19.5, *p* < 0.001) in parasite-infected erythrocytes was observed (Table 2) (Figure 2A and B). No significant statistical differences (*p* > 0.05) between the parasitaemia averages from adherent and non-adherent parasites were noticed.

Adherence of four *P. falciparum* isolates at basal state was 161.8 ± 196.2 and with TNF stimulation adhesion reach to 368.7 ± 429.1 (1.8-fold) and the adherence observed in the *P. falciparum* strain (FCR3) was 201 ± 61 parasite infected erythrocytes and after TNF stimulation it was 465 ± 498 (Table 2) (Figure 2C).

**Table 1 Percentage of cytoadherence of *Plasmodium vivax* isolates**

|          | Frequency | Percentage | Average parasitaemia parasites/μL (SD) | Significance (95%) |
|----------|-----------|------------|---------------------------------------|--------------------|
| *P. vivax* isolates | Adherent  | 13         | 9,461.5 (7766.1)                       | 0.122              |
|           | Non-adherent | 8         | 4,587.5 (4280.6)                       |                    |
| Total    | 21        | 100.0      |                                       |                    |

Total cytoadherence of *P. vivax* isolates, average parasitaemia and their standard deviations, significance value 95%.
The involvement of the ICAM-1 receptor (CD54) in parasite cytoadherence was determined in eight *P. vivax* isolates through cytoadherence inhibition assay using the monoclonal antibody anti-CD54 in TNF stimulated cells. A 50% cytoadherence reduction was observed in the average of adhered *Pv*-iEs/200 HMVEC-L, compared to cells without antibody anti-CD54, 62.7 ± 19.5 vs. 31.2 ± 8.8 *Pv*-iEs (Figure 3).

### Discussion

Cytoadherence of *P. vivax* isolates from Colombia was demonstrated using primary microvascular endothelial lung cells in static conditions as respiratory distress are one of the most frequently malaria vivax complication reported [26-29]. These assays revealed that the majority of *P. vivax* isolates, 13 out of 21 (61.9%), adhered to the lung endothelial cells and stimulation with TNF lead to a significant increase of 1.6-fold in *P. vivax* cytoadherence. Moreover, blockage of ICAM-1 receptor with specific antibodies showed a 50% significant reduction in parasite binding, thus demonstrating a *P. vivax* ability to adhere to the ICAM-1 receptor. As expected, *P. vivax* adherence was at least seven times lower in comparison to *P. falciparum* isolates. This latter finding is consistent with a previous report using Brazilian isolates [13].

The involvement of TNF in malaria pathogenesis has already been demonstrated in experimental cerebral malaria model [30]. The TNF released by monocytes in response to the endothelium damage or in the presence of soluble factors derived from the parasite such as glycosyl-phosphatidylinositol (GP-I) and haemozoin, increases ICAM-1 levels expressed in endothelial cells, and therefore enhances leukocytes and platelets adhesion and parasite sequestration to the endothelium [30,31]. Moreover, inflammatory co-morbidities, including

---

**Table 2 Cytoadherence of *Plasmodium vivax* and *Plasmodium falciparum* isolates in HMVEC-L basal and stimulated with TNF-α**

| Isolate (code) | Adherence<sup>1</sup> | Adherence (% of inhibition) Anti-CD54 |
|----------------|----------------------|---------------------------------------|
|                | Basal | Stimulated TNF-α |                                          |
| *P. vivax*     |       |                |                                          |
| 0.012          | 19.0 ± 1 | 27.0 ± 2 | ND                                      |
| 0.013          | 19.5 ± 2.5 | 39.5 ± 5.5 | ND                                      |
| 0.014          | 10.5 ± 1.5 | 33.5 ± 3.5 | ND                                      |
| 0.015          | 40.1 ± 1 | 24.5 ± 2.5 | ND                                      |
| 0.017          | 42.0 ± 4 | 51.0 ± 16 | ND                                      |
| 0.018          | 28.0 ± 3 | 52.0 ± 7 | 31.5 (39.4) |
| 0.019          | 38.0 ± 9 | 58.5 ± 6.5 | 34 (41.9) |
| 0.022          | 37.0 ± 11 | 81.5 ± 2.5 | 36.5 (55.2) |
| 0.024          | 53.0 ± 6 | 77.5 ± 10.5 | 33.5 (56.8) |
| 0.025          | 28.5 ± 6.5 | 67.5 ± 3.5 | 23.5 (56.8) |
| 0.026          | 55.5 ± 7.5 | 69.5 ± 11.5 | 27 (61.2) |
| 0.027          | 35.5 ± 10.5 | 47.0 ± 8 | 42 (10.6) |
| 0.028          | 22.0 ± 4 | 48.5 ± 4.5 | 22 (54.6) |

| *P. falciparum* |       |                |                |
| 0.033          | 58.5 ± 13.4 | 113 ± 16.9 |                |
| 0.034          | 17 ± 7.1 | 53 ± 8.5 |                |
| 0.035          | 475 ± 38.2 | 1050 ± 74.9 |                |
| 0.036          | 97 ± 8.5 | 259 ± 24 |                |
| FCR3           | 201 ± 49.8 | 465 ± 61 |                |

<sup>1</sup> Average ± standard deviation of *Pv*-iEs per 200 HMVEC-L.

*P. vivax* and *P. falciparum* isolates cytoadherence to microvascular line of human lung endothelium HMVEC-L, from the isolate code 0.018 – 0.028 the percentage of adherence inhibition is described, compared to endothelial cells treated with TNF.

---

**Figure 2 Cytoadherence of clinical isolates of *Plasmodium sp.* to human lung endothelial cells HMVEC-L A and B.** Cytoadherence of *Pv*-iEs to human lung endothelial cells HMVEC-L 1% Giemsa stain. C. Cytoadherence of *Pf*-iEs to human lung endothelial cells HMVEC-L A 100x, B 40x and C 40x objective.
bacterial infections, seem to play a key role in \textit{P. vivax} clinical complications [3]. Therefore, endothelial cells were treated with TNF prior to \textit{Pv-iE}s adhesion as demonstrated. These results suggest that in an ICAM-1 overexpression scenario due to high expression of TNF allowed \textit{P. vivax} to improve its adhesion ability. In order to explore this hypothesis, the ICAM-1 receptor was blocked using anti-CD54 showing an average reduction of 50\% in the cytoadherence in TNF stimulated cells; even in some of the isolates was below basal levels. This demonstrates its role in cytoadherence and suggests the participation of other endothelial receptors, such as hyaluronic acid (HA) and chondroitin sulphate A (CSA).

\textit{Plasmodium vivax} adherence to ICAM-1 receptor has already been suggest by Carvalho \textit{et al}., who demonstrated a significantly higher \textit{Pv-iE}s adherence to CHO ICAM-1 transfected cells in comparison to mock CHO. The findings by Bernabeu \textit{et al}. indicate the involvement of VIR-14 protein in ICAM-1 cytoadherence [18].

Collectively, this study reinforces the recent findings about \textit{P. vivax} ability to cytoadhere to endothelial cells and highlights the importance of ICAM-1 endothelial receptors in this phenomenon.

\textbf{Competing interests}

All authors declare that they have no competing interests.

\textbf{Authors' contributions}

BD carried out laboratory work, analysed the data and helped to draft the manuscript. AP participated in the data analyses and helped to draft the manuscript. SB and CS conceived and coordinated the study. BD, AP, SCPL and FTMC designed the study and performed the statistical analysis. All authors read and approved the final manuscript.

\textbf{Acknowledgments}

The authors would like to thank the patients for their willingness during the samples collection, and the Nuestra Señora del Carmen Hospital staff in El Bagre – Department of Antioquia for lending us the malaria sample collecting equipment, and the clinical laboratory for letting us use their equipment. Ana María Vásquez Cardona, PhD Biology student, for her unconditional support in the experimental development of the investigation, and the Grupo Malaria. This work was supported by Colciencias (Grant 111549326146, RC-489-2009) and the Universidad de Antioquia, Colombia (CODI- Estrategia de Sostenibilidad 2013–2014). BD, AP, CS and SB were supported by Colciencias (Grant 111549326146, RC-489-2009) and the Universidad de Antioquia, Colombia (CODI- Estrategia de Sostenibilidad 2013–2014). FTMC is enrolled at the Programa Estratégico de Ciencia, Tecnología & Inovação nas Fundações Estaduais de Saúde (PECTI/AM Saúde) from Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM, Amazonas - Brazil). SCPL was supported by a FAPESP fellowship and CNPq-Universal grant.

\textbf{Author details}

1 Grupo Malaria, Facultad de Medicina, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia. 2Programa de Biología, Facultad de Ciencias Básicas, Universidad del Atlántico, 080001, Barranquilla, Colombia. 3Departamento de Genética, Evolución e Bioagentes, Universidad Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.

\textbf{Received:} 29 July 2013 \textbf{Accepted:} 24 September 2013 \textbf{Published:} 30 September 2013

\textbf{References}

1. Muñoz I, Galinski MR, Baird JK, Catton JM, Kochar DK, Alonso PL, del Portillo HA: Key gaps in the knowledge of \textit{Plasmodium vivax}, a neglected human malaria parasite. \textit{Lancet Infect Dis} 2009, 9:655–666.
2. Tjitra E, Anstey NM, Sugirjo P, Warikar N, Kenangalem E, Kanya M, Lampah DA, Price RN: Multidrug-resistant \textit{Plasmodium vivax} associated with severe and fatal malaria: a prospective study in Papua, Indonesia. \textit{PLoS Med} 2008, 5:e227.
3. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes RL, Mourao MP, Lacerda MV, Alcênter M: Severe \textit{Plasmodium vivax} malaria, Brazilian Amazon. \textit{Emerg Infect Dis} 2010, 16:1611–1614.
4. Harish R, Gupta S: \textit{Plasmodium vivax} malaria presenting with severe thrombocytopenia, cerebral complications and hydrocephalus. \textit{Indian J Pediatr} 2009, 76:551–552.
5. Varte G, Goswami J, Vanikar A, Shah P, Gumber M, Patel H, Kanodia K, Trivedi H: Unusual presentation of \textit{Plasmodium vivax} malaria: a neglected human malaria parasite. \textit{Parasitol Res} 2012, 110:2573–2576.
6. Zubair* A, Fazal A, Raza A, Husain I, Beg A: Pulmonary complications of \textit{Plasmodium vivax} malaria. \textit{Chest} 2012, 142:194A.
7. George P, Alexander LM: A study on the clinical profile of complicated \textit{Plasmodium vivax} mono-infections. \textit{Asian Pac J Trop Med} 2010, 3:560–562.
8. Valecha N, Pinto RG, Turner GD, Kumar A, Rodrigues S, Dubhashi NG, Rodrigues E, Banaulkar SS, Singh P, Dash AP, Baird JK: Histopathology of fatal respiratory distress caused by \textit{Plasmodium vivax} malaria. \textit{Am J Trop Med Hyg} 2009, 81:758–762.
9. Arboleda M, Pérez MF, Fernández D, Usuga LY, Meza M: Perfil clínico y de laboratorio de los pacientes con malaria por \textit{Plasmodium vivax}, hospitalizados en Apartadó, Colombia. \textit{Biomédica} 2012, 32:56–67.
10. Tan LK, Yacob S, Scott S, Bhagani S, Jacobs M: Acute lung injury and other serious complications of \textit{Plasmodium vivax} malaria. \textit{Lancet Infect Dis} 2008, 8:449–454.
11. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Geler E, Crabtree J, Angnioulu SV, Merino EF, Arnedo P, Cheng Q, Coullson RM, Crabbs BS, Del Portillo HA, Essien K, Feldblyum TV, Gilson PR, Guo X, Kanyi S, Kooij TW,
Korsinczyk V, Meyer EV, Nene V, Paulsen J, Ralph V, Ren Q, Sargeant TJ, Salzberg SL, Stoeckert CJ, Sullivan SA, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. *Nature* 2008, 455:757–763.

12. Gupta P, Das A, Singh OP, Ghosh SK, Singh V. Assessing the genetic diversity of the vir genes in Indian *Plasmodium vivax* population. *Acta Trop* 2012, 124:133–139.

13. Carvalho BO, Lopes SCP, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, Marom O, Leite JA, Rodrigues MM, Soares IS, Oliveira TR, Wunderlich G, Lacerda MGV, Del Portillo HA, Araújo MOG, Russell B, Suwanarusk R, Snounou G, Rêmia L, Costa FTM. On the cytoadhesiveness of *Plasmodium vivax*-infected erythrocytes. *J Infect Dis* 2010, 202:638–647.

14. Anstey NM, Handjojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, Maguire GP. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. *J Infect Dis* 2007, 195:589–596.

15. Chotivanich K, Udomsangpetch R, Suwanarusk R, Pukrittayakamee S, Wilairatana P, Beeson JG, Day NP, White NJ. *Plasmodium vivax* adherence to placental glycosaminoglycans. *PLoS* One 2012, 7:e34509.

16. Oliveira T, Fernandez-Becerra C, Jimenez MC, Del Portillo H, Soares I. Evaluation of the acquired immune responses to *Plasmodium vivax* VIR variant antigens in individuals living in malaria-endemic areas of Brazil. *Malar J* 2006, 5:83.

17. Fernandez-Becerra C, Pein O, de Oliveira TR, Yamamoto MM, Cassola AC, Rocha C, Soares IS, de Bragança Pereira CA, del Portillo HA. Variant proteins of *Plasmodium vivax* are not donally expressed in natural infections. *Mol Microbiol* 2005, 58:458–468.

18. Bernabeu M, Lopez FJ, Ferrer M, Martin-Jaular L, Razaname A, Corradin G, Maier AG, del Portillo HA, Fernandez-Becerra C. Functional analysis of *Plasmodium vivax* VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor. *Cell Microbiol* 2012, 14:386–400.

19. Piñeros-Jiménez IG, Arboleda M, Jaramillo JC, Blair S. Reporte de cinco casos de malaria neonatal grave por *Plasmodium vivax* en Urabá, Colombia. *Biomedica* 2008, 28:471–479.

20. Carmona-Fonseca J, Maestre-B A. Incidencia de las malarías gestacional, congénita y placental en Urabá (Antioquia, Colombia), 2005–2007. *Rev Colomb Obstet Ginecol* 2009, 60:19–33.

21. Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science* 1976, 193:673–675.

22. Pabón A, Álvarez G, Yáñez J, Céspedes C, Rodríguez Y, Restrepo Á, Blair S. Evaluación de la prueba rápida inmunocromatográfica Binax NOW® ICT PF/Pv para el diagnóstico del paludismo en un área endémica de Colombia. *Biomedica* 2007, 27:225–235.

23. Fernández-V, Treutiger CJ, Nish GB, Wahlgen M. Multiple adhesive phenotypes linked to rosetting binding of erythrocytes in *Plasmodium falciparum* malaria. *Infect Immun* 1998, 66:2969–2975.

24. Goodyer ID, Johnson J, Eisenhal R, Hayes DJ. Purification of mature-stage *Plasmodium falciparum* by gelatine flotation. *Ann Trop Med Parasitol* 1994, 88:209–211.

25. Duraisingh MT, Rooper P, Walliker D, Warhurst DC. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of *Plasmodium falciparum*. *Mol Microbiol* 2000, 36:955–961.

26. Lomar AV, Vidal EV, Lomar FP, Barbosa CV, Matos GJ, Boulos M. Acute respiratory distress syndrome due to vivax malaria: case report and literature review. *Braz J Infect Dis* 2005, 9:225–340.

27. Kumar S, Melzer M, Dodds P, Watson J, Ord R. *Plasmodium vivax* malaria complicated by shock and ARDS. *Scand J Infect Dis* 2007, 39:255–256.

28. Tanios MA, Kogelman L, McGovern B, Hassoun PM. Acute respiratory distress syndrome complicating *Plasmodium vivax* malaria. *Crit Care Med* 2001, 29:655–667.

29. Martínez O. Síndrome de dificultad respiratoria aguda en malaria por *Plasmodium vivax*. *Acta Med Colomb* 1996, 21:146–150.

30. Engwerda C, Belnoue E, Gruner AC, Renia L. Experimental models of cerebral malaria. *Curr Top Microbiol Immunol* 2005, 297:103–143.

31. Coban C, Ishii KJ, Horii T, Akira S. Manipulation of host innate immune responses by the malaria parasite. *Trends Parasitol* 2007, 23:271–278.